Literature DB >> 6653389

Predictors of favorable outcome following naltrexone treatment.

R A Greenstein, B D Evans, A T McLellan, C P O'Brien.   

Abstract

In order to determine the type of patient most likely to benefit from opiate antagonist therapy, a series of multivariate regression analyses were performed on a sample of male veterans who completed induction on naltrexone. Patient background characteristics, demographic factors and during-treatment variables were used to predict outcome measured at 1-month follow-up. Employment at the start of naltrexone and length of naltrexone therapy were significantly related to better outcome at 1-month follow-up. Treatment duration was clearly the best outcome predictor. The finding that at least 30 days of naltrexone therapy was necessary for significant improvement at 1-month follow-up but that longer periods of treatment were not necessarily associated with greater gains suggests that treatment can be limited and still be relatively successful. A second set of analyses attempted to discover patient characteristics predictive of longer treatment duration. Results showed that patients who were employed and/or married at the start of naltrexone therapy were more likely to stay in treatment longer. Similar results have been obtained by others suggesting that these patients have the best family and social supports to sustain a positive treatment outcome. In addition, they may also be more 'motivated' since they have the most to lose personally and financially by readdiction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653389     DOI: 10.1016/0376-8716(83)90042-x

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  8 in total

1.  A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Tamara Y Boney; Cynthia A Clark; Joshua D Lee; Peter D Friedmann; Edward V Nunes; Timothy W Kinlock; Michael S Gordon; Robert P Schwartz; Elie S Nuwayser; Charles P O'Brien
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

2.  Treatment compliance in patients with comorbid psychiatric and substance use disorders.

Authors:  Diane M Herbeck; Diana J Fitek; Dace S Svikis; Ivan D Montoya; Steven C Marcus; Joyce C West
Journal:  Am J Addict       Date:  2005 May-Jun

Review 3.  Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

Authors:  Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland
Journal:  Lancet       Date:  2010-07-31       Impact factor: 79.321

4.  A randomized trial of oral naltrexone for treating opioid-dependent offenders.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Arthur I Alterman; Charles P O'Brien
Journal:  Am J Addict       Date:  2010 Sep-Oct

5.  Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence.

Authors:  Will M Aklin; S Geoffrey Severtson; Annie Umbricht; Michael Fingerhood; George E Bigelow; C W Lejuez; Kenneth Silverman
Journal:  J Clin Psychiatry       Date:  2012-08       Impact factor: 4.384

6.  Clinical care of the HIV-infected drug user.

Authors:  R Douglas Bruce; Frederick L Altice
Journal:  Infect Dis Clin North Am       Date:  2007-03       Impact factor: 5.982

Review 7.  Improving public health through access to and utilization of medication assisted treatment.

Authors:  Thomas F Kresina; Robert Lubran
Journal:  Int J Environ Res Public Health       Date:  2011-10-24       Impact factor: 3.390

Review 8.  Use of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary care.

Authors:  Jinhee Lee; Thomas F Kresina; Melinda Campopiano; Robert Lubran; H Westley Clark
Journal:  Biomed Res Int       Date:  2015-01-05       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.